drugset / Trial / NCT06601517
A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects.
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to characterize the effect of HDM1002 on the PK of single dose of repaglinide, atorvastatin, digoxin and rosuvastatin in healthy adult subjects. The safety and tolerability of HDM1002 with repaglinide, atorvastatin, digoxin and rosuvastatin when given separately or together will also be evaluated.
Timeline
- Start
- 2024-10
- Primary completion
- 2025-02
- Completion
- 2025-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atorvastatin | Small molecule | — | Oral |
| Subject | Digoxin | Other / unclassified | — | Oral |
| Subject | HDM1002 | Unknown | — | Oral |
| Subject | Repaglinide | Small molecule | — | Oral |
| Subject | Rosuvastatin | Small molecule | — | Oral |
Indications
No indication recorded.